ReviewDrug discovery today2008
Pandemic and seasonal influenza: therapeutic challenges.
Review in Drug discovery today, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Antiviral Activity of Angelica Tenuissima Nakai against Influenza A Virus.Pathogens (Basel, Switzerland) · 2024Article
- Design, synthesis and biological evaluation of sulfamethazine derivatives as potent neuraminidase inhibitors.Future medicinal chemistry · 2024Article
- The evolution and future of influenza pandemic preparedness.Experimental & molecular medicine · 2021Review
- Nanoparticle-Based Devices in the Control of Antibiotic Resistant Bacteria.Frontiers in microbiology · 2020Review
- Sialidases FromFrontiers in cellular and infection microbiology · 2019Review
- Directed Evolution of an Influenza Reporter Virus To Restore Replication and Virulence and Enhance Noninvasive Bioluminescence Imaging in Mice.Journal of virology · 2018Article
- The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection.Scientific reports · 2018Article
- Effects of Influenza on Alveolar Macrophage Viability Are Dependent on Mouse Genetic Strain.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Back to the Future: Lessons Learned From the 1918 Influenza Pandemic.Frontiers in cellular and infection microbiology · 2018Review
- Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems.Current pharmaceutical design · 2018Review
- Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.Biochemical and biophysical research communications · 2017Article
- Pandemics, public health emergencies and antimicrobial resistance - putting the threat in an epidemiologic and risk analysis context.Archives of public health = Archives belges de sante publique · 2017Article
- High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution.Scientific reports · 2014Article
- Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.Acta crystallographica. Section D, Biological crystallography · 2014Article
- How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth.Immunological reviews · 2013Review
- Transcriptional adaptation of pneumococci and human pharyngeal cells in the presence of a virus infection.BMC genomics · 2013Article
- A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2.PloS one · 2013Article
- Article
- In vitro inhibitory activity of Alpinia katsumadai extracts against influenza virus infection and hemagglutination.Virology journal · 2010Article
- Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Influenza A viruses cause significant morbidity and mortality annually, and the threat of a pandemic underscores the need for new therapeutic strategies. Here, we briefly discuss novel antiviral agents under investigation, the limitations of current antiviral therapy and stress the importance of secondary bacterial infections in seasonal and pandemic influenza. Additionally, the lack of new antibiotics available to treat increasingly drug resistant organisms such as methicillin-resistant Staphylococcus aureus, pneumococci, Acinetobacter, extended spectrum beta-lactamase producing gram negative bacteria and Clostridium difficile is highlighted as an important component of influenza treatment and pandemic preparedness. Addressing these problems will require a multidisciplinary approach, which includes the development of novel antivirals and new antibiotics, as well as a better understanding of the role secondary infections play on the morbidity and mortality of influenza infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.